Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHP674 in newly diagnosed untreated ALL
NCT04067518Phase 2Completed
- Sponsor
- Servier
- Start
- Oct 2019
- Primary completion
- Feb 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Servier. Primary endpoint: Treatment-Emergent Adverse Events at 49 weeks. Started Oct 2019; status: completed.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04067518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067518.